Tabrecta (capmatinib) has potential interactions with other medications and some supplements. These interactions could affect how well the drug works or cause harmful effects. Tabrecta is used in ...

Tabrecta approved in Europe Meanwhile, Novartis also has good news in its targeted oncology business on the other side of the Atlantic, as the European Commission has approved its Incyte-partnered ...

What is the current share price of Incyte Corp (INCY)? Incyte Corp's (INCY) current share price is $64.25. This constitutes a price movement of 1.48% when compared to the share price 7 days ago and is ...

In the US, it is competing in the METex14-positive NSCLC market with Novartis/Incyte's rival MET inhibitor Tabrecta (capmatinib). The EAMS opinion is based on results from the phase 2 VISION study ...

Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung ...

Personalized Circulating Tumor DNA Testing for Detection of Progression and Treatment Response Monitoring in Patients With Metastatic Invasive Lobular Carcinoma of the Breast This study identified ...

At close: May 27 at 4:00:01 PM EDT ...

Erleada Combo Shows Comparable Quality of Life Outcomes in Prostate Cancer ...

Immunotherapy helps your immune system to recognize and destroy cancer cells The drugs tend to work better in patients who have a higher level of a protein called PD-L1 The drugs were initially ...